Dr. Cusi has contributed to the field on the underlying mechanisms of NAFLD in obesity and diabetes and published the first RCT on pioglitazone for NASH for patients with prediabetes or T2DM (Belfort et al, NEJM 2006). This was followed by a recent long-term study confirming its value in this population (Cusi et al., Annals Intern Med 2016). Dr Cusi’s current work at the University of Florida centres on discovering the mechanism(s) leading to NASH and searching for novel treatments.
Dr Cusi has published more than 150 original articles, reviews and book chapters in a broad spectrum of peer-reviewed journals, such as the New England Journal of Medicine, Annals of Internal Medicine, Proceeding of the National Academy of Science, Journal of Clinical Investigation, Diabetes, Diabetes Care, J Clinical Endocrinology and Metabolism, American Journal of Physiology, Hepatology, Gastroenterology and others. He is an associate editor and reviewer for many journals in the fields of endocrinology, metabolism, diabetes and liver disease.
He is a frequently invited lecturer to national and international meetings on the role of obesity and NAFLD in T2DM. He is a member of the NIH Clinical and Integrative Diabetes and Obesity (CIDO) study section and contributed to the panel of the 2012 and 2017 NASH guidelines of the American Association for the Study of Liver Diseases. In 2015 Dr Cusi received two prestigious awards from the University of Florida, the Exemplary Teacher Award and the Clinical Research Award for outstanding achievement, research discovery, and productivity from the College of Medicine.